Autoplaque vs CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

Autoplaque is workstation-based post-processing software that provides automated segmentation which is reviewable and editable by clinicians, offering an interactive and efficient workflow for image analysis. Its analysis time of less than 2 seconds per lesion further enhances efficiency for radiologists and cardiologists. While CARTOu2122 3 EP aims for streamlined procedural workflow, Autoplaque's direct clinician control over AI outputs in a diagnostic setting suggests a more straightforward and user-controlled experience for image interpretation.

Both tools demonstrate significant clinical value in their respective, distinct domains. Autoplaque aids in heart attack risk prediction and treatment guidance through quantitative analysis of coronary plaques, with studies supporting its prognostic value for future cardiac events. CARTOu2122 3 EP enhances the diagnosis and treatment of complex heart rhythm disorders by improving the efficiency, reproducibility, and accuracy of 3D cardiac mapping and navigation during ablation procedures. Both are FDA-cleared and backed by clinical evidence, making them equally valuable in their specialized applications.

Both tools lack transparent public pricing, requiring direct consultation with sales representatives. However, CARTOu2122 3 EP, as a comprehensive 3D cardiac mapping and navigation system, involves a substantial capital investment, with typical system costs ranging from $150,000 to $250,000, plus significant ongoing expenses for maintenance and disposables. Autoplaque, being workstation-based software, is likely to have a considerably lower overall cost of acquisition and operation, suggesting a potentially higher value proposition for its specific diagnostic application.

CARTOu2122 3 EP demonstrates superior enterprise readiness with explicit statements of HIPAA compliance and Business Associate Agreements (BAA) for its associated cloud platform, CARTONETu2122, which also supports GDPR and integrates with SSO and role-based access control. Its deployment as an EP lab system from a major medical device company (Biosense Webster) implies robust infrastructure and support for large-scale clinical environments. Autoplaque, while workstation-based, lacks disclosed HIPAA/BAA information in the provided facts, which is a critical requirement for enterprise adoption in healthcare.

CARTOu2122 3 EP showcases a broader and more integrated application of AI and deep learning within a complex, real-time interventional workflow, including the first FDA-cleared AI algorithm in intracardiac ultrasound for automated 3D left atrial anatomy creation. Its multiple AI-powered modules (ELEVATE, CARTOSOUND FAM) and algorithms (Stability+) demonstrate a sophisticated and multi-faceted approach to enhancing procedural efficiency and accuracy. While Autoplaque's AI-powered quantitative plaque analysis is highly innovative for diagnostic imaging and risk prediction, CARTOu2122 3 EP's real-time, multi-modal AI integration in a surgical context represents a more advanced and complex innovation.

CARTOu2122 3 EP, offered by Biosense Webster (a Johnson & Johnson MedTech company), provides a comprehensive support ecosystem including clinical account specialists, training centers, on-screen troubleshooting, and readily available product resources and documentation. This indicates a robust and established support infrastructure typical of a large medical device manufacturer. Autoplaque, developed by an academic medical center and licensed to a startup, does not provide specific details on commercial support or documentation beyond a user manual, suggesting a less formalized or extensive support system for external users compared to Tool B.